TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked hope but also raised a fundamental question: how …
TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—and identifying key hub genes like RPS27A that could become therapeutic targets. Alzheimer’s disease is a disease of broken communication. The brain doesn’t just lose cells—it loses control, as genes …
TL;DR: Untreated depression increases miscarriage risk by 34% across nearly 9 million women, but antidepressants reduce that risk to 24%—meaning the medication is safer than the disease during pregnancy. For decades, obstetricians have asked the wrong question about depression in pregnancy. They worried: Is the antidepressant dangerous? New data suggests a more sobering reality—the untreated …
TL;DR: A pesticide sprayed on US crops decades ago more than doubles your risk of Parkinson’s disease, and new research shows exactly how it damages dopamine neurons. You probably never heard of chlorpyrifos, but your neighborhood may have been sprayed with it. This common agricultural insecticide was applied to millions of acres across California and …
TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “death complex” and prevents cognitive decline in mice. Alzheimer’s disease devastates the brain through multiple pathways, but the exact triggering mechanisms remain frustratingly unclear. A new study in Molecular …
TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific brain regions in patients with treatment-resistant depression — and where they go predicts who will respond to the drug. Nearly one in three people with depression fail …
TL;DR: A chemical messenger called nitric oxide triggers protein damage that sends the mTOR pathway into overdrive in autism-related mouse models, driving social deficits and repetitive behaviors—and blocking this mechanism reverses both the molecular dysfunction and autistic-like behaviors. Autism spectrum disorder involves dozens of genetic variants, yet many converge on a single pathway: mTOR, a …
TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated infusions. Ketamine works like almost nothing else in psychiatry. A single infusion can lift severe depression within hours, even in patients who’ve failed every other drug. The problem? The magic doesn’t …
TL;DR: Parasitic infections trigger a sophisticated cellular conversation in the gut that signals the brain to stop eating—a protective response that reveals how infection hijacks the gut-brain axis through epithelial cell crosstalk, acetylcholine release, and serotonin signaling. When you’re fighting an infection, appetite disappears. It feels intuitive—your body’s way of conserving energy for immune defense. …
TL;DR: Krill oil has a slight edge for inflammation due to astaxanthin, but fish oil wins for raising blood omega-3 levels and long-term cardiovascular outcomes. Fish oil has dominated the omega-3 supplement market for decades. But a smaller crustacean from Antarctic waters is making a quiet challenge: krill oil. Marketing claims abound—krill oil is more …
